Prostate Dose-painting Radiotherapy and Radiobiological Guided Optimisation Enhances the Therapeutic Ratio

Clinical Oncology

Volumn 28, Issue 3, 2016, Pages 165-170

  Uzan, J ^a   Nahum, A E ^a   Syndikus, I ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

Dose painting; prostate cancer; radiobiological modelling; toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL OUTCOME; FECES INCONTINENCE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HORMONAL THERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE; PROSTATE CANCER; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RECTUM HEMORRHAGE; THERAPEUTIC INDEX; TREATMENT PLANNING; URETHRA STENOSIS; URINARY FREQUENCY; URINARY URGENCY; CANCER GRADING; FIDUCIAL MARKER; FOLLOW UP; IMAGE GUIDED RADIOTHERAPY; IMAGE PROCESSING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANS AT RISK; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING SYSTEM; STANDARDS; TREATMENT OUTCOME;

AGED; FIDUCIAL MARKERS; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGANS AT RISK; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 85014537998     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.09.006     Document Type: Article

References (30)

1. [1] Dearnaley, D.P., Sydes, M.R., Graham, J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
2. [2] Fuchsjäger, M.H., Pucar, D., Zelefsky, M.J., et al. Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys 78 (2010), 743–750.
3. [3] Kasivisvanathan, V., Emberton, M., Ahmed, H.U., Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol 25 (2013), 461–473.
4. [4] Chopra, S., Toi, A., Taback, N., et al. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), e441–448.
5. [5] Arrayeh, E., Westphalen, A.C., Kurhanewicz, J., et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82 (2012), e787–793.
6. [6] Arumainayagam, N., Ahmed, H.U., Moore, C.M., et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 268 (2013), 761–769.
7. [7] Azzeroni, R., Maggio, A., Fiorino, C., et al. Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): sensitivity to TCP parameters. Phys Med 29 (2013), 592–598.
8. [8] Ruggieri, R., Naccarato, S., Nahum, A.E., Severe hypofractionation: the usefulness of non-homogeneous tumour dose delivery in counteracting tumour hypoxia. Acta Oncol 49 (2010), 1304–1314.
9. [9] Pinkawa, M., Piroth, M.D., Holy, R., et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol, 7, 2012, 14.
10. [10] Housri, N., Ning, H., Ondos, J., et al. Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys 80 (2011), 614–620.
11. [11] Wong, W.W., Schild, S.E., Vora, S.A., et al. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys 81 (2011), e423–429.
12. [12] Ost, P., Speleers, B., De Meerleer, G., et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 79 (2011), 920–926.
13. [13] Bauman, G., Haider, M., Van der Heide, U.A., Ménard, C., Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother Oncol 107 (2013), 274–281.
14. [14] Abdellatif, A., Craig, J., Jensen, M., et al. Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion. Med Phys 39 (2012), 1505–1517.
15. [15] Qi, X.S., Semenenko, V.A., Li, X.A., Improved critical structure sparing with biologically based IMRT optimization. Med Phys 36 (2009), 1790–1799.
16. [16] Barentsz, J.O., Richenberg, J., Clements, R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 22 (2012), 746–757.
17. [17] Engels, B., Soete, G., Th, Gevaert, et al. Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer. Radiother Oncol 111 (2014), 106–109.
18. [18] Niyazi, M., Bartenstein, P., Claus Belka, C., et al. Choline PET based dose-painting in prostate cancer – modelling of dose effects. Radiat Oncol, 5, 2010, 23.
19. [19] Dearnaley, D., Syndikus, I., Sumo, G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13 (2012), 43–54.
20. [20] Khor, R., Duchesne, G., Tai, K.H., et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 85 (2013), 679–685.
21. [21] Buettner, F., Gulliford, S.L., Webb, S., et al. The dose-response of the anal sphincter region –an analysis of data from the MRC RT01 trial. Radiother Oncol 103 (2012), 347–352.
22. [22] Fiorino, C., Valdagni, R., Rancati, T., Sanguineti, G., Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 93 (2009), 153–167.
23. [23] Ahmed, A.A., Egleston, B., Alcantara, P., et al. A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. Int J Radiat Oncol Biol Phys 86 (2013), 709–715.
24. [24] Uzan, J., Nahum, A.E., Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite. Br J Radiol 85 (2012), 1279–1286.
25. [25] Nahum, A.E., Uzan, J., (Radio)biological optimization of external-beam radiotherapy. Comput Math Meth Med, 2012, 2012, 329214.
26. [26] Peeters, S.T., Hoogeman, M.S., Heemsbergen, W.D., et al. Rectal bleeding, faecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modelling. Int J Radiat Oncol Biol Phys 66 (2006), 11–19.
27. [27] Rancati, T., Valdagni, R., Fiorino, C., et al. Pre-treatment nomograms predicting severe rectal toxicity after prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 72 (2008), S286–S287.
28. [28] Hoffmann, A.L., den Hertog, D., Siem, A.Y., Kaanders, J.H., Huizenga, H., Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects. Phys Med Biol 53:22 (2008), 6345–6362.
29. [29] Maggio, A., Fiorino, C., Mangili, P., et al. Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by helical tomotheraphy. Acta Oncol 50 (2011), 25–34.
30. [30] Lips, I.M., van der Heide, U.A., Haustermans, K., et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 12, 2011, 255.